ACTION TO CONTROL CARDIOVASCULAR RISKS IN DIABETES (ACCORD) TRIAL

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 ACCORD试验旨在评估控制2型(成人发病)糖尿病的不同方法，同时降低高血压和高胆固醇引起的心血管问题的风险。将有60个中心的1万名参与者参加；老年研究中心网站将有大约150名参与者。这三种干预措施都涉及FDA批准的药物治疗。所有受试者都将接受糖尿病治疗；50%将接受额外的血脂治疗，50%将接受血压治疗。主要结果是首次发生重大心血管疾病事件，如中风或非致命性心肌梗死。其次，将评估心血管事件、与健康相关的生活质量、成本效益、死亡率和微血管结果方面的治疗差异。结果将通过实验室测试、自我报告问卷和体检来衡量。监测将由老年研究中心(GRC)的工作人员进行。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The ACCORD trial is designed to evaluate different methods of controlling Type 2 (adult onset) diabetes while diminishing the risks of cardiovascular problems from high blood pressure and high cholesterol. Ten thousand participants in 60 centers will be enrolled; there will be approximately 150 enrollees at the Geriatric Research Center site. The three interventions all involve FDA-approved pharmacologic treatments. All subjects will receive treatment for diabetes; 50% will receive additional lipid treatment, and 50% will receive blood pressure treatment. The primary outcome is the first occurrence of a major cardiovascular disease event such as stroke or non-fatal MI. Secondarily, treatment differences in CV events, health-related quality of life, cost effectiveness, mortality, and microvascular outcomes will be evaluated. Outcomes will be measured by lab tests, self-reported questionnaires, and physical examinations. Monitoring will be done by the staff of the Geriatric Research Center (GRC).